Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2025 | The role of BCG in treating high-risk non-muscle invasive bladder cancer

Felix Guerrero-Ramos • 28 Mar 2025
EAU 2025
Bladder Cancer Genitourinary Cancer Antibodies Sasanlimab

Félix Guerrero-Ramos, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain, discusses the continued importance of bacillus Calmette-Guérin (BCG) in treating high-risk non–muscle-invasive bladder cancer (NMIBC), including carcinoma in situ (CIS). BCG can remain effective in reducing disease progression despite evolving guideline classifications, and trials evaluating BCG in combination with novel agents such as subcutaneous sasanlimab point to a future where BCG continues to serve as a foundational therapy alongside new treatment strategies. This interview was recorded at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.

All content is owned by Magdalen Medical Publishing (MMP) and protected under international copyright laws. All rights reserved.

More from Felix Guerrero-Ramos

Individualizing therapy beyond early cystectomy in high-risk NMIBC
0:57
Individualizing therapy beyond early cystectomy in high-risk NMIBC
Felix Guerrero-Ramos • 26 Feb 2026
Selecting patients with high-risk NMIBC for BCG-immunotherapy strategies
1:28
Selecting patients with high-risk NMIBC for BCG-immunotherapy strategies
Felix Guerrero-Ramos • 26 Feb 2026
Evolving management of high-risk BCG-unresponsive NMIBC
0:53
Evolving management of high-risk BCG-unresponsive NMIBC
Felix Guerrero-Ramos • 26 Feb 2026
CREST: exploratory analysis of sasanlimab and BCG in very high-risk NMIBC
0:49
CREST: exploratory analysis of sasanlimab and BCG in very high-risk NMIBC
Felix Guerrero-Ramos • 26 Feb 2026

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals